Fundz

ADC drug developer Trior raises $25M in Series C funding from Korea Development Bank, DS Asset Management, and others to advance platform technologies and drug pipelines.

PRIVATEOct 23, 2026

Amount Raised

$25 Million

Round Type

Series C

BiotechnologyHealth CareTherapeuticsPharmaceutical

Investors

Sneak Peek InvestmentsShinhan CapitalLSK InvestmentWoori Venture PartnersHoneypot VenturesTESS Investment PartnersSage One PartnersHB InvestmentDS Asset ManagementKorea Development Bank

Description

Trior, an antibody-drug conjugate therapeutics developer, closed a $25 million Series C round conducted as a multi-closing with two tranches. The first close brought $18 million from new investors including Korea Development Bank, DS Asset Management, HB Investment, SAGE ONE PARTNERS, and TESS Investment Partners. The second close added $6.8 million from existing investors including Woori Venture Partners, LSK Investment, Shinhan Capital, and Sneak Peek Investments. Trior plans to use the funds to advance its TROCAD and TROSIG platform technologies and accelerate development of its antibody therapeutic and ADC drug pipelines.

Who to call at Trior, and when

A new round usually means Trior is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Trior raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Trior, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Trior

About

Trior is a developer of antibody-drug conjugate (ADC) therapeutics with two proprietary platforms: TROCAD, a dual-function masking platform for improving therapeutic index of antibody-based therapies, and TROSIG, a linker-payload platform for enhancing drug stability and efficacy of ADCs. The company is developing its own antibody therapeutic and ADC drug pipelines while pursuing joint R&D and technology transfer partnerships with biotech companies and pharmaceutical firms.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Trior raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Trior's next move

See what Strategic adds

Trior raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.